Various animal models of pulmonary hypertension (PH) exist, among which injection of
monocrotaline (MCT) and exposure to hypoxia are used most frequently. These animal …

INTRODUCTION: Pulmonary arterial hypertension (PAH) is a rare syndrome of fatigue and
dyspnoea, caused by increased pulmonary vascular resistance and right heart failure …

Pulmonary arterial hypertension (PAH) is a progressive and lethal pulmonary vascular
disease (PVD). Although in recent years outcome has improved by new treatments that …

Pulmonary hypertension (PH) and its severe subtype pulmonary arterial hypertension (PAH)
encompass a set of multifactorial diseases defined by sustained elevation of pulmonary …

Idiopathic pulmonary artery hypertension (IPH) is a rare illness with a poor prognosis.
Whereas chronic intravenous prostacyclin relieves some of the symptoms of progressive …

Numerous molecular abnormalities have been described in pulmonary arterial hypertension
(PAH), complicating the translation of candidate therapies to patients because, typically, 1 …

Pulmonary hypertension may develop as a disease process specific to pulmonary arteries
with no identifiable cause or may occur in relation to other cardiopulmonary and systemic …

Pulmonary arterial hypertension (PAH) is a complex obliterative vascular disease. It remains
deadly despite an explosion of basic research over the past 20 years that identified myriads …

Pulmonary arterial hypertension (PAH) is a progressive cardiovascular disease
characterized by pulmonary vasculature reconstruction and right ventricular dysfunction. The …

Pulmonary arterial hypertension (PAH) is a debilitating multifactorial disease characterized
by progressive pulmonary vascular remodeling, elevated pulmonary arterial pressure, and …